sutent
(Sunitinib malate)U.S. Pharmaceuticals
Usage: SUTENT is indicated for adult patients with gastrointestinal stromal tumor (GIST) post-imatinib treatment, advanced renal cell carcinoma (RCC), adjuvant therapy for high-risk recurrent RCC post-nephrectomy, and progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in unresectable or metastatic stages.